Lv4
438 积分 2022-11-01 加入
The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index
1天前
待确认
ClonoSEQ assay for the detection of lymphoid malignancies
21天前
已完结
Accelerated Titration Designs for Phase I Clinical Trials in Oncology
22天前
已完结
The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience
1个月前
已完结
Reduced CAR T expansion post infusion is associated with poor survival in patients with large B cell lymphoma after two or more therapies
1个月前
已完结
Daratumumab at the frontiers of post-transplant refractory T-acute lymphoblastic leukemia—a worthwhile strategy?
1个月前
已完结
The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience
1个月前
已完结
Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia
1个月前
已完结
Phase II Study of Nelarabine (compound 506U78) in Children and Young Adults With Refractory T-Cell Malignancies: A Report From the Children’s Oncology Group
1个月前
已关闭
Phase I Study of 506U78 Administered on a Consecutive 5-Day Schedule in Children and Adults With Refractory Hematologic Malignancies
1个月前
已完结
皖公网安备34019202002308
